Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5433MR)

This product GTTS-WQ5433MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5433MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3485MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ5442MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ3041MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ45MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ6757MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ14629MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ514MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW